Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Dr Lennard Lee, an associate professor at the Centre of Immuno-oncology at the Nuffield Department of Medicine, was awarded the 'SciTech Superhero' award for 2024 by Sarah Munby, the Permanent Secretary in the Department of Science, Innovation and Technology at a ceremony in London last week.

Dr Lennard Lee receiving the DIST award

The award celebrates the contribution of individuals who embodies the values of the DSIT, and has been working to position the UK at the forefront of global scientific and technological advancement.

Since 2022, Lennard has been working within the expert exchange programme at the Office for Life Sciences, as part of NDM’s career development scheme.

Along with teams at the NDM, Lennard is working to empower the country to establish a UK cancer vaccine advance. The shared national aspiration is to place 10,000 patients through clinical trials, to make advances at early and late stage for many cancer subtypes, and stimulate a global cancer vaccine advance. He previously lead on other major UK projects, including the UK COVID Cancer programme, the pandemic lateral flow moonshot and the NHS-Galleri study.

Dr Lee said: 'Receiving this award from the Department of Science, Innovation and Trade means a lot to me. I am very grateful for NDM in empowering me to push research in cancer vaccines. For me, the award signifies not solely personal achievement, it reflects the support and encouragement from an amazing department, collaborators, friends and colleagues. Without their support, our successful research endeavour in initiating a UK cancer vaccine advance would not have happened.'